Biochemical response after 3-D conformal radiotherapy of localized prostate cancer to a total dose of 66 Gy. 4-Year results

Strahlentherapie und Onkologie

Volumn 178, Issue 10, 2002, Pages 542-547

  Wachter Gerstner, Natascha ^b   Wachter, Stefan ^b   Goldner, Gregor ^b   Nechvile, Elisabeth ^b   Pötter, Richard ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Hormones; Prostate cancer; Radiotherapy

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION RESPONSE; SEMINAL VESICLE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; TUMOR MARKERS, BIOLOGICAL;

EID: 0036790260     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-002-0963-2     Document Type: Article

References (36)

1. Akakura K, Bruchovsky N, Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate specific antigens. Cancer 1993;71:2782-90.
2. Anderson PR, Hanlon AL, Movsas B, Hanks GE. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation. Int J Radiat Oncol Biol Phys 1997;39:1025-30.
3. ASTRO Consensus PaneL. Consensus statement: Guidelines for PSA foLLowing radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
4. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
5. D'Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, Wein A, CoLeman CN. Equivalent biochemical failure free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys 1997;37:1053-8.
6. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically locaLized prostate cancer. JAMA 1998;280:969-74.
7. Duchesne GM, Bloomfield D, Wall P. Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies. Radiother Oncol 1996;38:7-12.
8. English HF, Kyprianou N, Issacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989;15:233-50.
9. Eulau SM, Corn BW. Combination of hormones and local therapies in locally advanced prostate carcinoma. Oncology 1996;10:1193-202.
10. Fieldname HJ. Vergleich der Spätnebenwirkungen bei konformaler gegenüber konventioneller Strahlentherapie des lokal begrenzten Prostatakarzinoms. Eine prospektiv randomisierte Studie. Strahlenther Onkol 1999;175:350-1.
11. Gerstner N, Wachter S, Dorner D, Goldner G, Colotto A, Pötter R. Significance of a rectal balloon as internal immobilization device in conformal radiotherapy of prostatic carcinoma. Strahlenther Onkol 1999;175:232-8.
12. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, Coia LR. Optimization of conformal radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:543-55.
13. Hanks GE, Schultheiss TE, Hunt M, Epstein BE. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1995;31:25-9.
14. Hanks GE, Lee WR, Hanlon AL, Hunt M, Kaplan E, Epstein BE., Movsas B, Schultheiss TE. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥ 10 ng/ml. Int J Radiat Oncol Biol Phys 1996;35:861-8.
15. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000;46:823-32.
16. Hellmann S, Welchselbaum RR. Androgen blockade increases progression-free survival rates for patients undergoing radiotherapy for prostate cancer. Conformal treatment reduces radiation toxicity. In mice, genetic radiotherapy can induce tumor necrosis at the molecular level. JAMA 1996;275:245-6.
17. Kattan MW, Easthan JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
18. Kupelian P, Katcher J, Levin HS, Klein EA. A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997;37:1043-52.
19. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA. Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of LocaLized prostate cancer. Int J Radiat Oncol Biol Phys 2000;46:567-74.
20. Kupelian PA, Buchsbaum JC, Reddy AC, Klein EA. Radiation dose response in patients with favorable localized prostate cancer (stage T1-T2, biopsy GLeason ≤ 6, and pretreatment prostate-specific antigen ≤ 10). Int J Radiat Oncol Biol Phys 2001;50:621-62.
21. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
22. Lee WR, Hanks GE, Hanlon AL, Schultheiss TE, Hunt MA. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional, conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 1996;35:251-7.
23. Martin T, Hey-Koch S, Strassmann G, Kolotas C, Battas D, Rogge B, Roddiger S, Vogt HG, Heyd R, Dannenberg T, Kurek R, Tunn U, Zamboglou N. 3-D interstitial HDR brachytherapy combined with 3-D external beam radiotherapy and androgen deprivation for prostate cancer. Preliminary results. Strahlenther Onkol 2000;176:361-7.
24. Nickers P, Coppens L, Beauduin M, Sabatier J, Albert A, de Leval, J, Deneufbourg JM. PSA kinetics after external beam radiotherapy alone or combined with an iridium brachytherapy boost to deliver 80 Grays to prostatic adenocarcinoma. Strahlenther Onkol 2001;177:90-5.
25. Pitepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grigno D. Phase III radiation therapy oncotogy group (RTOG) trial. 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
26. Pinover WH, Hanlon AL, Horwitz EM, Hanks GE. Defining the appropriate dose for prostate cancer patients with PSA < 10 ng/ml. Int J Radiat Oncol Biol Phys 1998;42:142.
27. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000;48:507-12.
28. Schulte RW, Slater JD, Rossi CJ, Stater JM. Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahtenther Onkol 2000;176:3-8.
29. Soffen EM, Hanks GE, Hunt MA, Epstein BE. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. IntJ Radiat Oncol Biol Phys 1992;24:485-8.
30. Vicini FA, Kini VR, Spencer W, Diokno A, Martinez AA. The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 1999;43:707-13.
31. Wachter S, Gerstner N, Dieckmann K, Stampfer M, Hawliczek R, Potter R. Planned 3-dimensional, low-volume conformal irradiation of a local prostatic carcinoma. Strahlenther Onkol 1997;173:253-60.
32. Wachter S, Gerstner N, Goldner G, Dieckmann K, Colotto A, Pötter R. Three dimensional conformal photon radiotherapy to a moderate dose level of 66 Gy for prostate carcinoma: early results. Strahlenther Onkol 1999;175: Suppl. 2:84-6.
33. Wachter S, Gerstner N, Domer D, Goldner G, Colotto A, Wambersie A, Pötter R. The influence of a rectal balloon tube as internal immobilisation device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (in press).
34. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
35. Zierhut D, Flentje M, Sroka-Perez G, Rudat V, Engenhart-Cabillic R, Wannenmacher M. The conformal radiotherapy of localized prostatic carcinoma: acute tolerance and early efficacy. Strahlenther Onkol 1997;173:98-105.
36. Zietman AL, Prince EA, Nakforr BM, Shipley WU. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology 1997;49:74-83.